Strata Critical Medical director sells 11,000 SRTA shares

Strata Critical Medical, Inc. reported an insider transaction by a director on a Form 4.

Rhea-AI Filing Summary

Strata Critical Medical, Inc. reported an insider transaction by a director on a Form 4. On 11/19/2025, the reporting person sold 11,000 shares of Class A common stock at a weighted average price of $4.3122 per share, with individual trade prices ranging from $4.31 to $4.32. After this sale, the director beneficially owns 124,897 shares of the company’s Class A common stock, held directly. No derivative securities transactions were reported in this filing.

Insider Trade Summary

Net Seller: 11,000 shares

Net Sell 1 txn

Insider Love Reginald

Role Director

Sold 11,000 shs ($47K)

Type	Security	Shares	Price	Value
Sale	Class A common stock, $0.0001 par value per share	11,000	$4.3122	$47K

Holdings After Transaction: Class A common stock, $0.0001 par value per share — 124,897 shares (Direct)

Footnotes (1)

1. F1. These transactions were executed in multiple trades at prices ranging from $4.31 to $4.32, inclusive. The price reported above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request to the SEC, the Issuer, or a security holder of the Issuer full information regarding the number of shares sold at each separate price within the range.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What insider transaction did Strata Critical Medical (SRTA) report on this Form 4?

The filing reports that a director of Strata Critical Medical, Inc. sold 11,000 shares of Class A common stock in a transaction dated 11/19/2025.

At what price were the Strata Critical Medical (SRTA) shares sold in this Form 4?

The shares were sold at a weighted average price of $4.3122 per share, with individual trade prices ranging from $4.31 to $4.32.

How many Strata Critical Medical (SRTA) shares does the director own after the reported sale?

Following the reported transaction, the director beneficially owns 124,897 shares of Strata Critical Medical’s Class A common stock, held directly.

What is the relationship of the reporting person to Strata Critical Medical (SRTA)?

The reporting person is identified as a director of Strata Critical Medical, Inc.

Does this Strata Critical Medical (SRTA) Form 4 include any derivative securities transactions?

No. The section for derivative securities shows no acquired or disposed derivative positions reported in this Form 4.

On what date was the earliest transaction in this Strata Critical Medical (SRTA) Form 4?

The earliest transaction date disclosed in the filing is 11/19/2025.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 11/20/2025 - 04:07 PM Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Love Reginald

(Last) (First) (Middle)

C/O STRATA CRITICAL MEDICAL, INC.

31 HUDSON YARDS, 14TH FLOOR

(Street)

NEW YORK NY 10001

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
Strata Critical Medical, Inc. [ SRTA ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

3. Date of Earliest Transaction (Month/Day/Year)
11/19/2025

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Class A common stock, $0.0001 par value per share	11/19/2025		S		11,000	D	$4.3122(1)	124,897	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. These transactions were executed in multiple trades at prices ranging from $4.31 to $4.32, inclusive. The price reported above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request to the SEC, the Issuer, or a security holder of the Issuer full information regarding the number of shares sold at each separate price within the range.

Remarks:

	/s/ Melissa M. Tomkiel, as attorney-in-fact for Reginald Love	11/20/2025
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.